Nune Makarova
Alnylam Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Blood Pressure and Hypertension Studies, Kidney Stones and Urolithiasis Treatments, Liver Disease Diagnosis and Treatment, Endoplasmic Reticulum Stress and Disease, Receptor Mechanisms and Signaling
Most-Cited Works
- → RNA Interference With Zilebesiran for Mild to Moderate Hypertension(2024)107 cited
- → Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension(2025)19 cited
- → Interim phase 1 part A results for ALN‐APP, the first investigational RNAi therapeutic in development for Alzheimer’s disease(2023)12 cited
- → ZILEBESIRAN AS ADD-ON THERAPY IN PATIENTS WITH HYPERTENSION INADEQUATELY CONTROLLED WITH A STANDARD ANTIHYPERTENSIVE MEDICATION: EFFICACY AND SAFETY RESULTS FROM THE KARDIA-2 STUDY(2024)9 cited
- → Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis(2025)8 cited
- → Efficacy and Safety of Lumasiran for Advanced Primary Hyperoxaluria Type 1: 24-Month Follow-up of the Phase 3 ILLUMINATE-C Trial(2025)6 cited
- → Phase 1 study of the RNA interference therapeutic ALN-HSD in healthy adults and patients with non-alcoholic steatohepatitis(2023)4 cited
- → Subgroup results from KARDIA-2: impact of demographic and baseline disease characteristics on zilebesiran response in patients with hypertension uncontrolled by a standard oral antihypertensive(2024)2 cited
- → CONSISTENT ANTIHYPERTENSIVE EFFICACY OF THE RNA INTERFERENCE THERAPEUTIC ZILEBESIRAN: SUBGROUP RESULTS FROM THE KARDIA-1 PHASE 2 STUDY IN PATIENTS WITH HYPERTENSION(2024)1 cited
- → Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial(2023)1 cited